Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS
This monocentric prospective study of patient suffering from Amyotrophic lateral sclerosis (ALS) aims to evaluate the prognosis and diagnostic potential of both Neurofilament-Light (Nf-L) and neuroinflammatory biomarkers in serum and CSF. Candidate markers levels were measured using multiplex method...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803734/ https://www.ncbi.nlm.nih.gov/pubmed/33436881 http://dx.doi.org/10.1038/s41598-020-80370-6 |
_version_ | 1783636006928384000 |
---|---|
author | Brodovitch, Alexandre Boucraut, José Delmont, Emilien Parlanti, Amandine Grapperon, Aude-Marie Attarian, Shahram Verschueren, Annie |
author_facet | Brodovitch, Alexandre Boucraut, José Delmont, Emilien Parlanti, Amandine Grapperon, Aude-Marie Attarian, Shahram Verschueren, Annie |
author_sort | Brodovitch, Alexandre |
collection | PubMed |
description | This monocentric prospective study of patient suffering from Amyotrophic lateral sclerosis (ALS) aims to evaluate the prognosis and diagnostic potential of both Neurofilament-Light (Nf-L) and neuroinflammatory biomarkers in serum and CSF. Candidate markers levels were measured using multiplex method in serum of 60 ALS patients, 94 healthy controls of 43 patients suffering from Inflammatory Peripheral Neuropathies (IPN). A comparative CSF analysis was performed for 20 ALS and 17 IPN patients. Among the altered biomarkers, CSF Nf-L level remains the best marker of ALS severity, while serum levels correlate strongly with disease progression. The combination of Nf-L and ICAM-1 concentrations in the CSF and IFN-γ concentration in the serum differentiate ALS patients from IPN patients with improved sensibility and specificity relative to individual biomarkers. A cutoff value of 0.49 for the fitted values of these 3 biomarkers discriminate ALS from IPN patients with a specificity of 100% (78.20–100%) and a sensibility of 85.71% (57.19–98.22%) with an AUC of 0.99 ± 0.01. The measure of Nf-L and neuroinflammatory biomarkers in CSF and serum can be useful biomarkers panel in the differential diagnosis of ALS. |
format | Online Article Text |
id | pubmed-7803734 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-78037342021-01-13 Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS Brodovitch, Alexandre Boucraut, José Delmont, Emilien Parlanti, Amandine Grapperon, Aude-Marie Attarian, Shahram Verschueren, Annie Sci Rep Article This monocentric prospective study of patient suffering from Amyotrophic lateral sclerosis (ALS) aims to evaluate the prognosis and diagnostic potential of both Neurofilament-Light (Nf-L) and neuroinflammatory biomarkers in serum and CSF. Candidate markers levels were measured using multiplex method in serum of 60 ALS patients, 94 healthy controls of 43 patients suffering from Inflammatory Peripheral Neuropathies (IPN). A comparative CSF analysis was performed for 20 ALS and 17 IPN patients. Among the altered biomarkers, CSF Nf-L level remains the best marker of ALS severity, while serum levels correlate strongly with disease progression. The combination of Nf-L and ICAM-1 concentrations in the CSF and IFN-γ concentration in the serum differentiate ALS patients from IPN patients with improved sensibility and specificity relative to individual biomarkers. A cutoff value of 0.49 for the fitted values of these 3 biomarkers discriminate ALS from IPN patients with a specificity of 100% (78.20–100%) and a sensibility of 85.71% (57.19–98.22%) with an AUC of 0.99 ± 0.01. The measure of Nf-L and neuroinflammatory biomarkers in CSF and serum can be useful biomarkers panel in the differential diagnosis of ALS. Nature Publishing Group UK 2021-01-12 /pmc/articles/PMC7803734/ /pubmed/33436881 http://dx.doi.org/10.1038/s41598-020-80370-6 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Brodovitch, Alexandre Boucraut, José Delmont, Emilien Parlanti, Amandine Grapperon, Aude-Marie Attarian, Shahram Verschueren, Annie Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS |
title | Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS |
title_full | Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS |
title_fullStr | Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS |
title_full_unstemmed | Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS |
title_short | Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS |
title_sort | combination of serum and csf neurofilament-light and neuroinflammatory biomarkers to evaluate als |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803734/ https://www.ncbi.nlm.nih.gov/pubmed/33436881 http://dx.doi.org/10.1038/s41598-020-80370-6 |
work_keys_str_mv | AT brodovitchalexandre combinationofserumandcsfneurofilamentlightandneuroinflammatorybiomarkerstoevaluateals AT boucrautjose combinationofserumandcsfneurofilamentlightandneuroinflammatorybiomarkerstoevaluateals AT delmontemilien combinationofserumandcsfneurofilamentlightandneuroinflammatorybiomarkerstoevaluateals AT parlantiamandine combinationofserumandcsfneurofilamentlightandneuroinflammatorybiomarkerstoevaluateals AT grapperonaudemarie combinationofserumandcsfneurofilamentlightandneuroinflammatorybiomarkerstoevaluateals AT attarianshahram combinationofserumandcsfneurofilamentlightandneuroinflammatorybiomarkerstoevaluateals AT verschuerenannie combinationofserumandcsfneurofilamentlightandneuroinflammatorybiomarkerstoevaluateals |